Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2012 | 1 |
2014 | 3 |
2015 | 3 |
2024 | 1 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Science. 2014 Dec 19;346(6216):1480-6. doi: 10.1126/science.1254721. Epub 2014 Nov 13.
Science. 2014.
PMID: 25394791
Free PMC article.
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R, Lovly CM, Shaw AT.
Katayama R, et al.
Clin Cancer Res. 2015 May 15;21(10):2227-35. doi: 10.1158/1078-0432.CCR-14-2791.
Clin Cancer Res. 2015.
PMID: 25979929
Free PMC article.
Review.
Item in Clipboard
Apoptosis in targeted therapy responses: the role of BIM.
Faber AC, Ebi H, Costa C, Engelman JA.
Faber AC, et al.
Adv Pharmacol. 2012;65:519-42. doi: 10.1016/B978-0-12-397927-8.00016-6.
Adv Pharmacol. 2012.
PMID: 22959036
Review.
Item in Clipboard
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.
Hata AN, Engelman JA, Faber AC.
Hata AN, et al.
Cancer Discov. 2015 May;5(5):475-87. doi: 10.1158/2159-8290.CD-15-0011. Epub 2015 Apr 20.
Cancer Discov. 2015.
PMID: 25895919
Free PMC article.
Review.
Item in Clipboard
Advances and future directions in ROS1 fusion-positive lung cancer.
Boulanger MC, Schneider JL, Lin JJ.
Boulanger MC, et al.
Oncologist. 2024 Aug 23:oyae205. doi: 10.1093/oncolo/oyae205. Online ahead of print.
Oncologist. 2024.
PMID: 39177972
Free article.
Item in Clipboard
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N.
Katayama R, et al.
Clin Cancer Res. 2015 Jan 1;21(1):166-74. doi: 10.1158/1078-0432.CCR-14-1385. Epub 2014 Oct 28.
Clin Cancer Res. 2015.
PMID: 25351743
Free PMC article.
Item in Clipboard
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman JA, Shaw AT.
Katayama R, et al.
Clin Cancer Res. 2014 Nov 15;20(22):5686-96. doi: 10.1158/1078-0432.CCR-14-1511. Epub 2014 Sep 16.
Clin Cancer Res. 2014.
PMID: 25228534
Free PMC article.
Item in Clipboard
Cite
Cite